ALX Oncology (ALXO) vs Eledon Pharmaceuticals (ELDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eledon Pharmaceuticals (ELDN) has outperformed ALX Oncology (ALXO) over the past year, gaining 23.6% versus a loss of 25.9%. Over five years, ELDN leads with a -65.6% price change compared with -96.8% for ALXO. Eledon Pharmaceuticals is the larger company by market cap ($150.3 million vs $137.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | ELDN |
|---|---|---|
| Share price | $1.06 | $1.78 |
| Market cap | $137.03M | $150.34M |
| 1-day change | +3.92% | -6.32% |
| YTD return | -6.19% | +17.88% |
| 1-year return | -25.87% | +23.61% |
| 5-year return | -96.84% | -65.64% |
| EPS (TTM) | $-0.87 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-101.69M | $-45.62M |
| 52-week high | $2.66 | $4.49 |
| 52-week low | $0.862 | $1.39 |
| Distance from 52-week high | -60.15% | -60.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +333.96% | +405.62% |
| Average volume | 1.19M | 931.77K |
| Shares outstanding | 129.27M | 84.46M |
| Employees | 49 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELDN has outperformed ALXO by 49.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
ALXO vs ELDN FAQ
Which is bigger, ALX Oncology or Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $150.34M compared with $137.03M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or ELDN?
ELDN returned +23.61% over the past 12 months, compared with -25.87% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Eledon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.